DT
PT
Subscribe To Print Edition About The Tribune Code Of Ethics Download App Advertise with us Classifieds
search-icon-img
search-icon-img
Advertisement

Amanta Healthcare Limited IPO Opens on September 01, 2025

  • fb
  • twitter
  • whatsapp
  • whatsapp
Advertisement

Mumbai (Maharashtra) [India], August 26: Amanta Healthcare Limited, a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenterals (LVPs and SVPs), proposes to open its Initial Public Offering on September 01, 2025, aiming to raise ₹ 12,600.00 Lakhs (at upper price band) with shares to be listed on the NSE and BSE Platform. The issue size is up to 1,00,00,000 equity shares with a face value of ₹ 10 each with a price band of ₹ 120 - ₹ 126 Per Equity Share.

Advertisement

Equity Share Allocation • Qualified Institutional Buyer – Not more than 50,00,000Equity Shares • Non-Institutional Investors - Not less than 15,00,000Equity Shares • Individual Investors - Not less than 35,00,000 Equity Shares The net proceeds from the IPO will be utilized for funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat, funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat, and general corporate purposes. The anchor portion will open on Friday, August 29, 2025 and the issue will close on Wednesday, September 03, 2025.

The Book Running Lead Manager to the Issue is Beeline Capital Advisors Private Limited, and the Registrar is MUFG Intime India Private Limited (Formerly Known as Link Intime India Private Limited).

Advertisement

Mr. Bhavesh Patel, Chairman and Managing Director of Amanta Healthcare Limited expressed, “Our company has grown by developing and supplying a wide range of sterile liquid products across therapeutic segments and medical devices. We have established a presence across domestic and international markets. This IPO marks a step forward in our growth journey, allowing us to expand our manufacturing capabilities with new SteriPort and SVP lines at our Hariyalafacility, which will strengthen our capacity and support us for Future plans.

(Disclaimer: The above press release comes to you under an arrangement with PNN and PTI takes no editorial responsibility for the same.). PTI PWR

Advertisement

(This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.)

Advertisement
Advertisement
Advertisement
tlbr_img1 Classifieds tlbr_img2 Videos tlbr_img3 Premium tlbr_img4 E-Paper tlbr_img5 Shorts